Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation
Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation
复制标题
Asunaprevir/daclatasvir 和 sofosbuvir/ledipasvir 治疗活体肝移植后复发性丙型肝炎
作者：
K. Omichi;N. Akamatsu;Kazuhiro Mori;J. Togashi;J. Arita;J. Kaneko;K. Hasegawa;Y. Sakamoto;N. Kokudo
本研究旨在阐明使用asunaprevir和daclatasvir或sofosbuvir和ledipasvir的无干扰素治疗用于患有丙型肝炎病毒（HCV）的活体肝移植（LDLT）受者的疗效和安全性。
This study aimed to clarify the efficacy and safety of interferon‐free therapy using asunaprevir and daclatasvir, or sofosbuvir and ledipasvir for post living donor liver transplantation (LDLT) recipients with hepatitis C virus (HCV).
影响因子：
29.4
作者：
Forman, LM;Lewis, JD;Lucey, MR
通讯作者：
Lucey, MR